Data gathered: January 2
AI Stock Analysis - Vertex Pharmaceuticals (VRTX)
Analysis generated December 29, 2024. Powered by Chat GPT.
Vertex Pharmaceuticals is a global biotechnology company focused on the discovery, development, and commercialization of innovative new medicines for serious diseases. The company is primarily involved in developing therapies for cystic fibrosis and has a robust pipeline of potential treatments for other serious illnesses. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex has established a strong presence in the biotech sector through its groundbreaking research and significant contributions to medical science.
Stock Alerts - Vertex Pharmaceuticals (VRTX)
 |
Vertex Pharmaceuticals | December 19 Price is down by -12.7% in the last 24h. |
|
Vertex Pharmaceuticals | December 10 Over the past few months, there has been an upward trend in Web Traffic. |
|
Vertex Pharmaceuticals | December 9 Ro Khanna (member of U.S. congress) is buying shares |
|
Vertex Pharmaceuticals | November 15 Price is down by -5.3% in the last 24h. |
Alternative Data for Vertex Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 188 | Sign up | Sign up | Sign up |
| Sentiment | 82 | Sign up | Sign up | Sign up |
| Webpage traffic | 293,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | 15 | Sign up | Sign up | Sign up |
| Patents | 283 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 11,188 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,616 | Sign up | Sign up | Sign up |
| Twitter Followers | 71,481 | Sign up | Sign up | Sign up |
| Twitter Mentions | 104 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 2,350 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | 50 | Sign up | Sign up | Sign up |
| ESG | 68 | Sign up | Sign up | Sign up |
| Business Outlook | 89 | Sign up | Sign up | Sign up |
| Linkedin Employees | 6,096 | Sign up | Sign up | Sign up |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
| Price | $402.70 |
| Target Price | Sign up |
| Volume | 1,050,000 |
| Market Cap | $104B |
| Year Range | $392.81 - $516.74 |
| Dividend Yield | 0% |
| PE Ratio | 32.11 |
| Analyst Rating | 62% buy |
| Industry | Biotechnology |
In the news
 |
Jim Cramer’s Take on Vertex Pharmaceuticals (VRTX): Bold Predictions for the FutureJanuary 1 - Yahoo Entertainment |
 |
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowDecember 31 - Yahoo |
 |
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for InvestorsDecember 31 - Yahoo |
 |
Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) three years ago are up 79%December 30 - Yahoo |
 |
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain InvestedDecember 30 - SeekingAlpha |
 |
SK Wealth Management LLC Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)December 30 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2.77B | 764M | 2.01B | 1.05B | 0 | 4.380 |
| Q2 '24 | 2.65B | 744M | 1.9B | -3.59B | -3.47B | -12.830 |
| Q1 '24 | 2.68B | 685M | 1.99B | 1.1B | 1.19B | 4.760 |
| Q4 '23 | 2.49B | 782M | 1.7B | 969M | 1.02B | 4.200 |
| Q3 '23 | 2.47B | 583M | 1.89B | 1.04B | 1.24B | 4.080 |
Insider Transactions View All
| ALTSHULER DAVID filed to sell 25,813 shares at $478.6. November 19 '24 |
| WAGNER CHARLES F JR filed to sell 44,137 shares at $518.3. November 13 '24 |
| Kewalramani Reshma filed to sell 75,772 shares at $515. November 12 '24 |
| Biller Jonathan filed to sell 16,651 shares at $461.7. October 3 '24 |
| Bhatia Sangeeta N. filed to sell 4,435 shares at $500. September 4 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Dec 6, 24 | Buy | $1K - $15K |
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Nov 8, 23 | Buy | $1K - $15K |
Read more about Vertex Pharmaceuticals (VRTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Vertex Pharmaceuticals?
The Market Cap of Vertex Pharmaceuticals is $104B.
What is Vertex Pharmaceuticals' PE Ratio?
As of today, Vertex Pharmaceuticals' PE (Price to Earnings) ratio is 32.11.
What is the current stock price of Vertex Pharmaceuticals?
Currently, the price of one share of Vertex Pharmaceuticals stock is $402.70.
How can I analyze the VRTX stock price chart for investment decisions?
The VRTX stock price chart above provides a comprehensive visual representation of Vertex Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vertex Pharmaceuticals shares. Our platform offers an up-to-date VRTX stock price chart, along with technical data analysis and alternative data insights.
Does VRTX offer dividends to its shareholders?
As of our latest update, Vertex Pharmaceuticals (VRTX) does not offer dividends to its shareholders. Investors interested in Vertex Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Vertex Pharmaceuticals?
Some of the similar stocks of Vertex Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.